VELA Investment Management LLC Has $3.44 Million Stock Holdings in Indivior PLC $INDV

VELA Investment Management LLC boosted its holdings in shares of Indivior PLC (NASDAQ:INDV) by 35.7% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 142,511 shares of the company’s stock after buying an additional 37,484 shares during the period. VELA Investment Management LLC’s holdings in Indivior were worth $3,436,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. CWM LLC purchased a new position in Indivior during the 3rd quarter valued at about $25,000. Raymond James Financial Inc. purchased a new position in Indivior during the second quarter valued at approximately $26,000. Amalgamated Bank acquired a new position in Indivior in the 2nd quarter valued at approximately $61,000. Mirae Asset Global Investments Co. Ltd. lifted its position in Indivior by 16.0% in the 2nd quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,820 shares of the company’s stock worth $71,000 after buying an additional 666 shares in the last quarter. Finally, Blue Trust Inc. acquired a new stake in shares of Indivior during the 3rd quarter valued at $99,000. 60.33% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on INDV shares. HC Wainwright boosted their price target on shares of Indivior from $35.00 to $48.00 and gave the company a “buy” rating in a report on Monday, January 12th. Northland Securities set a $50.00 target price on Indivior in a research note on Tuesday. Craig Hallum reaffirmed a “buy” rating and issued a $41.00 target price on shares of Indivior in a research report on Friday, October 31st. Weiss Ratings reiterated a “hold (c)” rating on shares of Indivior in a report on Friday, October 31st. Finally, Zacks Research cut Indivior from a “strong-buy” rating to a “hold” rating in a research note on Tuesday, January 13th. One equities research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and two have given a Hold rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and an average price target of $36.00.

Indivior Stock Performance

Shares of INDV stock opened at $32.98 on Thursday. The stock’s 50 day simple moving average is $34.47 and its 200 day simple moving average is $26.99. Indivior PLC has a twelve month low of $7.62 and a twelve month high of $38.00. The company has a market capitalization of $4.12 billion, a price-to-earnings ratio of 35.85 and a beta of 0.75.

Indivior (NASDAQ:INDV) last announced its quarterly earnings results on Thursday, October 30th. The company reported $0.72 EPS for the quarter, beating the consensus estimate of $0.38 by $0.34. Indivior had a negative return on equity of 90.79% and a net margin of 9.83%.The company had revenue of $314.00 million for the quarter, compared to the consensus estimate of $257.66 million. On average, analysts forecast that Indivior PLC will post 1.22 EPS for the current fiscal year.

Insider Activity

In other news, Director Barbara Ryan purchased 775 shares of the firm’s stock in a transaction on Monday, January 5th. The stock was bought at an average cost of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the acquisition, the director directly owned 1,963 shares of the company’s stock, valued at approximately $69,470.57. The trade was a 65.24% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Mark Stejbach acquired 775 shares of the company’s stock in a transaction dated Monday, January 5th. The stock was acquired at an average price of $35.39 per share, for a total transaction of $27,427.25. Following the completion of the purchase, the director directly owned 16,847 shares of the company’s stock, valued at $596,215.33. This trade represents a 4.82% increase in their position. The disclosure for this purchase is available in the SEC filing. Over the last 90 days, insiders have acquired 4,871 shares of company stock worth $172,385.

About Indivior

Indivior plc is a specialty pharmaceutical company dedicated to developing and delivering treatments for addiction and related mental health disorders. The company’s portfolio centers on therapies designed to support individuals dealing with opioid dependence, alcohol use disorder and other behavioral health challenges. Its lead products include Suboxone® (buprenorphine and naloxone) sublingual film and Sublocade® (extended-release buprenorphine) injection, both of which are approved in multiple markets to aid in opioid use disorder management.

Indivior was established in 2014 through a demerger from the pharmaceuticals division of Reckitt Benckiser Group plc, inheriting decades of research and commercial expertise in addiction medicine.